Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days.
But these endorsements haven't lifted Recursion shares out of a slump.
RXRX 1Y mountain Recursion shares over the past year.
The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research.
SDGR 1Y mountain Schrodinger shares over the past year.
Persons:
Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar
Organizations:
Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's
Locations:
U.S, biopharma, Biohive